NC 300 Pill - purple capsule/oblong, 20mm
Pill with imprint NC 300 is Purple, Capsule/Oblong and has been identified as Carbamazepine Extended Release 300 mg. It is supplied by Nostrum Laboratories, Inc.
Carbamazepine is used in the treatment of Trigeminal Neuralgia; Bipolar Disorder; Schizoaffective Disorder; Epilepsy; Seizures and belongs to the drug class dibenzazepine anticonvulsants. There is positive evidence of human fetal risk during pregnancy. Carbamazepine 300 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for NC 300
Carbamazepine Extended Release
- Imprint
- NC 300
- Strength
- 300 mg
- Color
- Purple
- Size
- 20.00 mm
- Shape
- Capsule/Oblong
- Availability
- Prescription only
- Drug Class
- Dibenzazepine anticonvulsants
- Pregnancy Category
- D - Positive evidence of risk
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Nostrum Laboratories, Inc.
- National Drug Code (NDC)
- 29033-0004
- Inactive Ingredients
-
ethylcellulose (20 mPa.s),
silicon dioxide,
sodium lauryl sulfate,
microcrystalline cellulose,
oleic acid,
medium-chain triglycerides,
hypromellose 2910 (6 mPa.s),
polyethylene glycol,
D&C Red No. 28,
FD&C Blue No. 1,
gelatin,
ferrosoferric oxide,
titanium dioxide,
D&C Yellow No. 10,
aluminum oxide,
FD&C Blue No. 2,
FD&C Red No. 40,
shellac
Note: Inactive ingredients may vary.
Related images for "NC 300"
More about carbamazepine
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (348)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Drug class: dibenzazepine anticonvulsants
- Breastfeeding
- En español
Patient resources
Other brands
Tegretol, Carbatrol, Tegretol XR, Epitol, ... +2 more
Professional resources
- Carbamazepine monograph
- Carbamazepine Capsules (FDA)
- Carbamazepine Chewable (FDA)
- Carbamazepine ER (FDA)
- Carbamazepine Oral Suspension (FDA)
Other brands
Tegretol, Carbatrol, Epitol, Equetro, Carnexiv
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.